Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinoma.
Timeframe: 2022 – 2024 Goal: Advance immunotherapy for FLC, by defining the most promising immunological targets that can be translated into effective cell-based immunotherapies Principal Investigators: Praveen Sethupathy, PhD, Biomedical Sciences, Cornell University; Mark Yarchoan, MD, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Paul G. Thomas, PhD, Immunology, St. Jude Children’s Research Hospital …